Inzy earnings
Web12 apr. 2024 · Inozyme Pharma Inc., whose market valuation is $224.17 million at the time of this writing, is expected to release its quarterly earnings report May 08, 2024 – May 12, 2024. Investors’ optimism about the company’s current quarter earnings report is understandable.
Inzy earnings
Did you know?
WebEarnings Summary For their last quarter, Inozyme Pharma (INZY) reported earnings of -$0.38 per share, beating the Zacks Consensus Estimate of $-0.43 per share. This reflects a positive... WebSee Inozyme Pharma, Inc. (INZY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Web29 mrt. 2024 · Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Jefferies Financial Group issued their Q1 2024 earnings estimates for shares of Inozyme Pharma in a research note issued on Wednesday, March 22nd.Jefferies Financial Group analyst S. Jeong anticipates that the company will earn ($0.44) per share for the quarter. Jefferies … Web6 apr. 2024 · Jefferies Financial Group Weighs in on Inozyme Pharma, Inc.'s Q1 2024 Earnings (NASDAQ:INZY) americanbankingnews.com - March 29 at 1:38 AM: Here's Why Inozyme Pharma Has My Attention finance.yahoo.com - March 28 at 10:53 AM: Q1 2024 EPS Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY) Increased by Analyst …
Web27 mrt. 2024 · Shares of NASDAQ:INZY opened at $3.60 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 8.93 and a quick ratio of 11.11. Inozyme Pharma has a 1-year low of $0.99 and a ... Web13 apr. 2024 · We use cookies to personalize content and ads, provide social media features, and, analyze our traffic. We also share information about your use of our site …
Web11 apr. 2024 · BOSTON, April 11, 2024 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman …
Web12 apr. 2024 · Shares of Lithia Motors stock opened at $227.63 on Wednesday. The firm has a market capitalization of $6.22 billion, a P/E ratio of 5.17, a price-to-earnings-growth ratio of 1.51 and a beta of 1. ... share direct loginWeb27 mrt. 2024 · Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) – Equities researchers at Wedbush upped their Q1 2024 earnings estimates for shares of Inozyme Pharma in a report issued on Wednesday, March 22nd. shared iphoto album on pcWeb31 mrt. 2024 · INZY Inozyme Pharma, Inc. Earnings Surprise 745 followers $5.73 1.04 ( +22.17%) 4:00 PM 03/31/23 NASDAQ $USD Post-Market: $5.67 -0.06 (-1.05%) 7:56 PM Summary Ratings Financials Earnings... shared ipodWeb12 apr. 2024 · Inozyme Pharma is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks. Summary Inozyme Pharma beats RenovoRx on 7 of the ... pool strainer cartridgeWebFor their last quarter, Inozyme Pharma (INZY) reported earnings of -$0.38 per share, beating the Zacks Consensus Estimate of $-0.43 per share. This reflects a positive … pools toysWebINZY - Inozyme Pharma, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. × publish chart save to portfolio create alert compare perf. Candle - advanced Intraday Daily Weekly Draw Fullscreen Settings INZY - Stock Price Chart INZY [NASD] Inozyme Pharma, Inc. pool stores winchester vaWebYou can buy and sell Inozyme Pharma (INZY) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. … pool store supplies near me